These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
545 related articles for article (PubMed ID: 21317394)
1. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394 [TBL] [Abstract][Full Text] [Related]
2. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer. Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927 [TBL] [Abstract][Full Text] [Related]
3. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. Sui Q; Zhang J; Sun X; Zhang C; Han Q; Tian Z J Immunol; 2014 Aug; 193(4):2016-23. PubMed ID: 25015826 [TBL] [Abstract][Full Text] [Related]
4. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related]
5. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Xiang R; Lode HN; Dreier T; Gillies SD; Reisfeld RA Cancer Res; 1998 Sep; 58(17):3918-25. PubMed ID: 9731503 [TBL] [Abstract][Full Text] [Related]
6. KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma. Malaisé M; Rovira J; Renner P; Eggenhofer E; Sabet-Baktach M; Lantow M; Lang SA; Koehl GE; Farkas SA; Loss M; Agha A; Campistol JM; Schlitt HJ; Geissler EK; Kroemer A J Immunol; 2014 Feb; 192(4):1954-61. PubMed ID: 24415778 [TBL] [Abstract][Full Text] [Related]
7. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model. Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275 [TBL] [Abstract][Full Text] [Related]
8. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells. Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295 [TBL] [Abstract][Full Text] [Related]
9. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546 [TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733 [TBL] [Abstract][Full Text] [Related]
12. An IL-12/Shh-C domain fusion protein-based IL-12 autocrine loop for sustained natural killer cell activation. Zhu L; Zhao Z; Wei Y; Marcotte W; Wagner TE; Yu X Int J Oncol; 2012 Aug; 41(2):661-9. PubMed ID: 22581115 [TBL] [Abstract][Full Text] [Related]
13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. Mulé JJ; Yang J; Shu S; Rosenberg SA J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106 [TBL] [Abstract][Full Text] [Related]
14. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Xiang R; Lode HN; Dolman CS; Dreier T; Varki NM; Qian X; Lo KM; Lan Y; Super M; Gillies SD; Reisfeld RA Cancer Res; 1997 Nov; 57(21):4948-55. PubMed ID: 9354462 [TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475 [TBL] [Abstract][Full Text] [Related]
16. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Kurooka M; Kaneda Y Cancer Res; 2007 Jan; 67(1):227-36. PubMed ID: 17210703 [TBL] [Abstract][Full Text] [Related]
17. IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice. Xia J; Liu W; Hu B; Tian Z; Yang Y Clin Immunol; 2010 Feb; 134(2):130-9. PubMed ID: 19875339 [TBL] [Abstract][Full Text] [Related]
18. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405 [TBL] [Abstract][Full Text] [Related]
19. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo. Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157 [TBL] [Abstract][Full Text] [Related]
20. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]